Expression of HER-2/neu in Oral Squamous Cell Carcinoma.
Fluorescence in Situ Hybridization
Human epidermal growth factor receptor-2
erbB2
immunohistochemistry
oral cancer
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 May 2020
01 May 2020
Historique:
received:
17
02
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
3
2
2021
Statut:
epublish
Résumé
HER-2/neu is a member of the human epidermal growth factor (HER) family of transmembrane tyrosine kinases, which is significantly associated with the pathogenesis of various cancer types. The aim was to evaluate the expression of HER-2/neu in oral squamous cell carcinoma (OSCC) as a potential biomarker to target antigens for specific immunotherapy in OSCC. One hundred and forty histologically diagnosed OSCC cases were identified. Four to five-micrometer thick formalin-fixed, paraffin-embedded tumor sections were stained with Haematoxylin and Eosin (H and E). Histological grade was assessed according to WHO/Broders classification, while tumors were staged according to the American Joint Committee on Cancer (AJCC) TNM classification from stage I to IV. Immunohistochemistry was performed by using Rabbit monoclonal antibody against HER-2/neu (EP700Y, cell marquee and diluted 1:50). FISH was performed on positive cases using Vysis PathVysion HER-2 DNA probe (Abbott USA). Probes consist of LSI HER gene spectrum orange and control probe CEP 17 spectrum green. In this study, males were mostly effected (64.3%) with buccal mucosa (49%) to be the commonly involved site for OSCC. Majority of cases were moderately differentiated (62.1%) and 50.7% tumors were Stage IV. HER-2/neu was found to be positive (2+) in one case of OSCC, however weak to moderate complete membrane staining was observed in >10% of the tumor cells. One hundred and thirty nine cases were HER-2/neu negative. FISH analysis of HER-2/neu positive cases also showed gene amplification (Her2-neu/ CEp 17 = 225/33 = 7.2). The study showed disparity in the expression of HER-2/neu in OSCC, which is due to multiple reasons. Therefore therapy against HER-2/neu in OSCC is debatable.
Sections du résumé
BACKGROUND
BACKGROUND
HER-2/neu is a member of the human epidermal growth factor (HER) family of transmembrane tyrosine kinases, which is significantly associated with the pathogenesis of various cancer types. The aim was to evaluate the expression of HER-2/neu in oral squamous cell carcinoma (OSCC) as a potential biomarker to target antigens for specific immunotherapy in OSCC.
METHODS
METHODS
One hundred and forty histologically diagnosed OSCC cases were identified. Four to five-micrometer thick formalin-fixed, paraffin-embedded tumor sections were stained with Haematoxylin and Eosin (H and E). Histological grade was assessed according to WHO/Broders classification, while tumors were staged according to the American Joint Committee on Cancer (AJCC) TNM classification from stage I to IV. Immunohistochemistry was performed by using Rabbit monoclonal antibody against HER-2/neu (EP700Y, cell marquee and diluted 1:50). FISH was performed on positive cases using Vysis PathVysion HER-2 DNA probe (Abbott USA). Probes consist of LSI HER gene spectrum orange and control probe CEP 17 spectrum green.
RESULTS
RESULTS
In this study, males were mostly effected (64.3%) with buccal mucosa (49%) to be the commonly involved site for OSCC. Majority of cases were moderately differentiated (62.1%) and 50.7% tumors were Stage IV. HER-2/neu was found to be positive (2+) in one case of OSCC, however weak to moderate complete membrane staining was observed in >10% of the tumor cells. One hundred and thirty nine cases were HER-2/neu negative. FISH analysis of HER-2/neu positive cases also showed gene amplification (Her2-neu/ CEp 17 = 225/33 = 7.2).
CONCLUSIONS
CONCLUSIONS
The study showed disparity in the expression of HER-2/neu in OSCC, which is due to multiple reasons. Therefore therapy against HER-2/neu in OSCC is debatable.
Identifiants
pubmed: 32458657
doi: 10.31557/APJCP.2020.21.5.1465
pmc: PMC7541867
pii:
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1465-1470Références
J Cancer Res Ther. 2018 Jan-Mar;14(2):388-393
pubmed: 29516925
Anticancer Res. 1992 May-Jun;12(3):613-9
pubmed: 1377893
Cancer Growth Metastasis. 2017 Feb 16;10:1179064417690543
pubmed: 28469470
Anticancer Res. 1992 Nov-Dec;12(6B):2273-6
pubmed: 1363518
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):661-4
pubmed: 19827890
Clin Cancer Res. 1999 Dec;5(12):4164-74
pubmed: 10632356
J Pathol. 2004 Nov;204(3):317-25
pubmed: 15476268
Heliyon. 2016 Dec 05;2(12):e00206
pubmed: 27981249
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Anticancer Res. 1997 Nov-Dec;17(6D):4539-46
pubmed: 9494565
Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1265-70
pubmed: 7576473
J Oral Maxillofac Pathol. 2013 May;17(2):240-7
pubmed: 24250086
Clin Cancer Res. 2002 Feb;8(2):540-8
pubmed: 11839675
J Exp Clin Cancer Res. 2010 Apr 29;29:40
pubmed: 20429940
Asian Pac J Cancer Prev. 2012;13(6):2891-6
pubmed: 22938479
J Oral Pathol Med. 2008 Mar;37(3):145-50
pubmed: 18251938
Pediatr Surg Int. 2006 Nov;22(11):891-6
pubmed: 16932912
Head Neck Pathol. 2007 Dec;1(2):181-5
pubmed: 20614273
Clin Lung Cancer. 2017 Jan;18(1):92-95
pubmed: 27497829
Int J Oncol. 2005 May;26(5):1177-85
pubmed: 15809707
JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):559-67
pubmed: 27077364
Br J Cancer. 2003 Aug 18;89(4):681-6
pubmed: 12915878
Oral Oncol. 2008 Mar;44(3):227-35
pubmed: 17604679
Clin Cancer Res. 1997 Jan;3(1):3-9
pubmed: 9815530
J Pathol. 2001 Oct;195(3):343-8
pubmed: 11673832
Cancer Lett. 2002 Oct 28;184(2):223-30
pubmed: 12127695
Int J Cancer. 2018 Sep 1;143(5):1114-1127
pubmed: 29607493
Head Neck. 2007 Jul;29(7):655-64
pubmed: 17315173
J Dent Res. 2008 Jan;87(1):14-32
pubmed: 18096889
J Clin Oncol. 2001 Jan 15;19(2):354-63
pubmed: 11208826
Adv Pharm Bull. 2015 Dec;5(Suppl 1):649-52
pubmed: 26793611
Iran J Otorhinolaryngol. 2012 Fall;24(69):161-70
pubmed: 24303404
Rom J Morphol Embryol. 2012;53(3):597-601
pubmed: 22990553
Patholog Res Int. 2010 Dec 06;2011:674182
pubmed: 21188213
J Chin Med Assoc. 2008 Mar;71(3):123-7
pubmed: 18364263
Int J Cancer. 2000 Apr 15;86(2):269-75
pubmed: 10738256
Cancer. 1991 Apr 15;67(8):2142-9
pubmed: 1672262
Anticancer Res. 2013 Jun;33(6):2509-15
pubmed: 23749902
Oral Oncol. 2001 Jan;37(1):50-6
pubmed: 11120483
Cancer Biol Med. 2018 Nov;15(4):375-388
pubmed: 30766749
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Oral Pathol Med. 2014 Apr;43(4):304-8
pubmed: 24645976
Int J Oral Maxillofac Surg. 1998 Jun;27(3):209-12
pubmed: 9662015
Rom J Morphol Embryol. 2013;54(4):1107-13
pubmed: 24399009
J Thorac Oncol. 2010 Dec;5(12):1922-32
pubmed: 21155183